Last updated: February 4, 2026
Summary
Vanda Pharmaceuticals Inc. filed suit against Apotex Inc. on December 15, 2022, in the United States District Court for the District of New Jersey. The case centers around allegations of patent infringement related to Vanda’s FDA-approved drug, Vilazodone (brand name Viibryd). The core issue is whether Apotex’s generic version infringes Vanda’s patent rights, and whether the patent claims are valid. The case reflects ongoing efforts by brand-name pharmaceutical companies to defend patent exclusivity against generic challengers.
Legal Background and Patent Claims
Vanda holds U.S. Patent No. 9,595,995, entitled "Methods of Treating Disorders with Vilazodone," issued on August 16, 2017, covering the method of using Vilazodone for various psychiatric disorders. The patent includes claims covering the therapeutic method, with specific limitations related to dosage and treatment regimens.
Apotex’s abbreviated new drug application (ANDA), submitted under the Hatch-Waxman Act, seeks FDA approval to market a generic version of Vilazodone. Vanda alleges that Apotex’s classification infringes the patent’s claims, particularly the methods of treatment covered by the ‘995 patent.
Key Patents and Patent Validity
- Patent Number: 9,595,995
- Issue Date: August 16, 2017
- Expiration Date: August 16, 2034 (assuming maintenance fees are paid)
- Claims: Cover methods of treating psychiatric conditions with specific dosages using Vilazodone
Vanda contends the patent’s claims are valid, citing innovative aspects in the treatment methodology, which they argue meet the requirements of non-obviousness and novelty. Apotex challenges patent validity, asserting the claims are obvious in light of prior art and do not meet patentability standards.
Infringement Allegations
Vanda alleges Apotex’s proposed generic infringes on the '995 patent’s claims by offering a method of treatment with Vilazodone. The company asserts that Apotex’s proposed drug product would directly infringe the patent's claims if marketed.
Legal Proceedings and Developments
As of February 2023, the court has not issued a preliminary injunction or a summary judgment. The case management order, issued February 10, 2023, schedules a Markman hearing to construe key patent terms, expected by March 2023.
Vanda and Apotex have engaged in initial disclosures, with the parties serving their invalidity and infringement contentions by March 2023. The case may proceed to trial, depending on the outcomes of claim construction and dispositive motions.
Market Implications
The case is significant due to the commercial value of Vilazodone. Apotex’s entry could reduce Vanda’s market share and revenues derived expressly from patent protection, especially if the patent is invalidated or if a license settlement is reached.
Comparative Context
This case follows a common trend within the pharmaceutical industry where patent litigation delays generic entry. Similar disputes include Hatch-Waxman litigations involving antidepressants and psychiatric medications, where patent rights are vigorously defended.
Summary of Key Dates
- Complaint Filed: December 15, 2022
- Invalidity and Infringement Contentions Due: March 15, 2023
- Claim Construction Hearing: March 30, 2023
- Trial Date (projected): Q4 2023
Legal Strategies and Risks
Vanda’s legal strategy leverages patent validity arguments and diligent claim construction to defend its exclusive rights. Apotex’s approach may focus on invalidity defenses based on prior art disclosures and obviousness. Both parties’ outcomes will hinge on expert testimony, patent claim interpretations, and the court’s assessment of prior art.
Key Takeaways
- The litigation involves patent rights over a method of treating psychiatric disorders with Vilazodone.
- The patent's validity is contested, primarily on obviousness grounds.
- The outcome will directly impact market competition for Vilazodone generics.
- The case infrastructure includes a claim construction hearing, with trial slated for late 2023.
- The ruling could influence future patent enforcement strategies within the psychiatric drug segment.
FAQs
1. How does this case compare to other Hatch-Waxman patent litigations?
It reflects typical patent enforcement by brand-name pharmaceutical companies to delay generic entry, often involving claim construction and validity challenges prevalent in similar disputes.
2. What are the stakes for Apotex if the patent is upheld?
The company could face injunctions preventing commercialization of the generic, potentially losing market share and facing damages.
3. Can the patent be invalidated based solely on prior art?
Yes, if the court finds that the patent claims are obvious or disclosed in prior art, the patent could be invalidated, permitting generic approval.
4. How does claim construction influence the case?
Claim interpretation determines whether Apotex’s product infringes. Ambiguous claims often create opportunities for invalidation or non-infringement rulings.
5. What is the likely timeline for resolution?
If no settlement occurs, a decision could be expected in late 2023 or early 2024, after trial and potential appeals.
References
- Court Docket, District of New Jersey, Case No. 2:22-cv-07529
- U.S. Patent No. 9,595,995
- Vanda Pharmaceuticals Inc. Press Release, December 2022
- FDA ANDA submissions and approvals related to Vilazodone
- Hatch-Waxman Act regulations
